Technology



Powerful workflows for highly sensitive identification and quantification of host cell proteins (HCPs)

Featuring the SCIEX OS software and the ZenoTOF 7600 system

Zhengwei Chen¹, Lei Xiong¹, Greg Adams², Hunter Walker², Margo Wilson², Leon Pybus³, Charles Heise³, Michelle Lyons³, Benjamin Hastings³ ¹SCIEX, USA; ²FUJIFILM Diosynth Biotechnologies, Morrisville, NC, USA; ³FUJIFILM Diosynth Biotechnologies, Teeside, UK

HCPs were confidently identified in final drug substance (DS) utilizing a data-dependent acquisition (DDA) approach on the ZenoTOF 7600 system. MS1-based quantification revealed decreasing levels of the HCPs for different purification stages. In addition, a targeted approach was used to further improve the specificity and sensitivity of very low-level HCPs.

HCPs can lead to degradation of biotherapeutic products or cause immune response in patients. Careful identification and monitoring of these proteins are vital in ensuring safe and effective drugs. Unique challenges exist in developing analytical methods for their confident identification and quantification. On the one hand, the concentration of HCPs can span over 5 orders of magnitude at different purification stages, requiring the analytical method covers a wide dynamic range. Meanwhile, low levels of HCPs (<1 ppm) can still exist in the final DS, imposing challenges on a method's sensitivity. Although off-the-shelf ELISA-based assays provide an easy and fast way to detect HCPs, they offer total HCP levels without information on individual HCPs. Anti-HCP polyclonal antibody sera raised in chicken, rabbits or other sources may not comprehensively recognize all HCPs in a sample or can lead to over- or underestimation of the HCP content depending on the immunogenicity

of HCPs. Furthermore, lack of specific HCP information undermines efforts of improving purifications steps efficiently.

To overcome these challenges, an LC-MS/MS DDA approach for highly confident identification of each individual HCP across samples with a wide dynamic range was used. The ultrasensitive MRM^{HR} method enabled quantification of HCPs down to sub-ppm level with the ZenoTOF 7600 system (Figure 1).

Key features of the HCP identification and quantification workflow

- Highest flexibility for reliable identification and ultra-sensitive quantification of HCPs down to sub-ppm level utilizing the capabilities of the ZenoTOF 7600 system
- Confident HCP identification based on high spectral MS/MS quality of DDA enhanced by the Zeno trap and simultaneous MS1-based quantification
- High-throughput workflow to monitor multiple HCPs levels across different purification stages from early material to final drug product with SCIEX OS software on MS1 or MS/MS level



Figure 1. A comprehensive HCP workflow for identification and quantification. Identification of HCPs was achieved by DDA including a database search using ProteinPilot software. For quantification, 2 options exist, which are MS1-based and MS/MS-based quantification. MS1-based quantification is a convenient way of leveraging the same data for identification. Higher specificity can be achieved with MS/MS-based quantification either using the non-targeted SWATH acquisition approach for generic quantification or a targeted approach using MRM^{HR} for HCPs of interest.



Methods

Sample preparation: HCP samples from a Chinese hamster ovary (CHO) cell culture harvest were first loaded onto a protein an affinity column (ProA), then to cation exchange chromatography (CEX), flowthrough anion exchange chromatography (AEX), followed by a virus filtration (VF) step to obtain the final bulk drug substance (BDS). Samples were collected for LC-MS analyses after each purification stage to monitor the HCPs levels in the intermediate samples and to evaluate the efficiency of HCP removal for each purification stage. Native digestion was performed for the samples as described previously.¹ In brief, 1M Tris-HCI (pH 8.4) was added to 600 µg of protein sample to obtain a final concentration of 25mM Tris-HCI. 20 ppm bovine serum albumin (BSA) were added as internal standard. Protein digestion was performed by adding trypsin at an enzyme-to-protein ratio of 1:400 and incubated at 37°C overnight. Dithiothreitol was added at a final concentration of 0.5 µg/µL and the solution was heated to 90°C for 10 min. Insoluble residues were spun down by centrifugation at 13,000×g for 2 min. Supernatants were carefully transferred into a fresh vial and acidified with trifluoroacidic acid to a final concentration of 0.05%. Protein digests at an equivalent of 160 µg of total protein were injected into the LC-MS system for analysis.

Chromatography: Protein digest was injected onto an ACQUITY CSH C18 column (2.1 x 150 mm, 1.7 μ m, 130 Å, Waters) with column temperature set at 50°C. The LC profile was 60 min with 0.1% formic acid in water and 0.1% FA in acetonitrile as mobiles phases at flow rate of 0.25 mL/min. Detailed LC information is shown in Table 1.

Table 1. Gradient used for LC separation.

Time (min)	%A	%B
0	99	1
3.0	99	1
48.0	60	40
50.0	10	90
53.0	10	90
53.1	99	1
60.0	99	1

Mass spectrometry: LC-MS/MS data in DDA and a targeted approach allowing for parallel reaction monitoring (MRM^{HR}) were acquired with the ZenoTOF 7600 system operated with SCIEX

OS software 2.1. Key TOF MS and TOF MS/MS parameters are listed in tables 2–4.

Table 2. TOF MS parameters.

Parameter	Value	Parameter	Value
lon source gas 1	50 psi	Source temperature	e 450°C
lon source gas 2	50 psi	lon Spray voltage	5500 V
Curtain gas	35 psi	CAD gas	7
Polarity	positive	Accumulation time	0.2 s
MS range	300–2000 m/z	Time bins to sum	8
Declustering potential	80 V	Collision energy	12 V

Table 3. TOF MS/MS DDA parameters.

Parameter	Value	Parameter	Value
Fragmentation mode	CID	Accumulation time	0.025 s
MS/MS range	100–2000 m/z	Time bins to sum	10
Declustering potential	80 V	Collision energy	Dynamic collision
#MS/MS per circle	30	Exclusion width	6 s for 2 occurrences
Q1 resolution	Unit	Zeno trap	On
CE spread	5 V	Zeno trap threshold	1 100,000

Table 4. TOF MS/MS MRM^{HR} parameters.

Parameter	Value	Parameter	Value
Fragmentation mode	CID	Accumulation time	0.025
MS/MS range	200–1500 m/z	Time bins to sum	10
Declustering potential	80 V	Scan schedule	Applied
Q1 resolution	Unit	Zeno Trap	On
CE spread	5 V	Zeno trap threshold	100,000
Optimized collision energy	Applied	Source/gas parameters	Same as Table 2



Data processing: DDA data were searched against a CHO protein database based on Uniprot entries, modified with the antibody, BSA and common human-derived impurity sequences, using ProteinPilot software 5.0. Using Skyline software, the best 3 transitions were determined for subsequent quantification. DDA and MRM^{HR} data were processed in SCIEX OS software for HCPs quantification on MS1 and MS/MS level, respectively. The spiked-in BSA standard was used to create ratios between detected HCP and standard to calculate ppm values.

Comprehensive workflows for HCPs analyses addressing different user needs

To answer the question of which HCPs are present in the samples and at what levels, effective workflows, capable of both identification and quantification, are needed. The ZenoTOF 7600 system provides versatile solutions to answer these questions while meeting different user needs (Figure 1):

- DDA for enhanced identification of HCPs through the Zeno trap, enabling MS1-based quantification, simultaneously
- MRM^{HR} for targeted quantification at the MS/MS level of dozens of user-defined HCPs
- SWATH acquisition for quantification of hundreds to thousands of proteins at MS/MS level in a single injection without prior knowledge of the HCPs in the sample

The risk of missing low abundance HCP is mitigated by ultra-fast and sensitive DDA, which generates a wealth of high-resolution MS/MS spectra benefiting from the superior scan speed of >100 Hz of the ZenoTOF 7600 system.^{2,3} Empowered by the newly introduced Zeno trap, high-quality MS/MS data can be achieved even for low-level HCPs by a 5-20x sensitivity (signal-to-noise) increase at MS/MS level.³ The speed combined with sensitivity improvements provide highly confident identifications of HCPs using database search engines. Besides the identification of HCPs, MS1 information can be extracted from the DDA dataset for relative guantification of HCPs without the need for any additional injection or method optimization. With the intuitive SCIEX OS software, the DDA acquisition method set-up is convenient and quantitative data processing in SCIEX OS software based on results of database searches is straightforward.

To further improve the detection and quantification of HCPs at very low levels by increasing specificity and minimizing the influence of interferences, the ZenoTOF 7600 system provides the capability for MS/MS-based quantification via 2 different strategies, MRM^{HR} or SWATH acquisition. As a data-independent acquisition (DIA) method, SWATH acquisition enables fragmentation of all species in each given *m/z*-window avoiding the pitfall of missing some low abundance species.

Thus, hundreds to thousands of HCPs can be quantified in a single run without the need for prior knowledge of the sample's HCP profile, nor any extensive method development. The MS/MS quantification based on SWATH acquisition is a generic, untargeted quantification approach. Alternatively, targeted quantification can be performed based on an MRM^{HR} method, if the interest lies in a limited number of known HCPs. This approach provides the benefit of further sensitivity gains, since the most intense peptides are selected and fragmented with optimized collision energies. While being more sensitive, this approach is limited to monitoring a limited number of HCPs and requires more knowledge of the HCPs for method optimization.

To summarize, having DDA, SWATH acquisition and MRM^{HR} approaches available on a single instrument platform dramatically improves the capabilities and flexibility for solid HCP identification and highly sensitive quantification.

HCP identification

The common strategy to identify HCPs is based on processing data from DDA through a database search engine, matching the empirical data with theoretical sequences from the host cell, such as, Chinese Hamster Ovary (CHO) cells or similar. Different database search engines can be used dependent on user access and user preferences. Here, the DDA data were processed with ProteinPilot software and searched against a CHO protein database including the sequences of the antibody therapeutic, BSA and common human-derived protein impurities. The search results (Figure 2) provided important information, such as, protein sequence coverage, peptide identification and identified peptide fragments. This information was subsequently used for selecting signature peptides and best transitions for quantification. MS/MS scoring as well as false-discovery rate analyses can provide statistical measures to judge data quality and limit false positive results. ProteinPilot software provides visualization of annotated MS/MS spectra, detailed fragments tables for intuitive confirmation and confidence scoring for peptides as well as proteins (Figure 2). Aside from the result files from ProteinPilot software which can easily be imported into Skyline software, serving as peptide library for processing of SWATH acquisition data files (not shown).



	Рго	tein ID				F	eatures			Spectra	1			Summary Statistics					
Proteins De	etected																		
N Unus	ed	Accessio	an#					Name				Total	% V	Peptides(95%)	Gene Onto	oav	Pathway		
2 24.	05 tr/G3GVD	OIG3GVD0 CRK	GR	ACTE	3 OS=Cricetulu	is griseus	: OX=100	29 GN=Actb PE=3 SV=1				24.04	65.1	16	adherens junctio	n; api	ļ		
5 13.	51 triG3GUN	IGIG3GUM6 CRI	GR	Glyce	eraldehyde-3-i	- ohosphate	e dehydro	agenase OS=Cricetulus aris	seus OX=1	0029 GN=I79 001391 PE=	-3 S	13.51	45.4	7	NAD binding: ox	idored			
6 13.	08 trjG3HSX	8 G3HSX8_CRIG	R	Biglyo	can OS=Cricel	ulus grise	eus OX=1	0029 GN=I79_013977 PE=3	SV=1	-		Dura				ellu			
1 38.	17 trjG3HNJ3	BIG3HNJ3_CRIGI	R	Cluste	erin OS=Crice	tulus grise	eus OX=1	0029 GN=Clu PE=3 SV=1				Pro	tein	Identificat	ions	I pe		-	
33 2.	67 trjG3IDL7	G3IDL7_CRIGR		Heat	shock cognat	e 71 kDa	protein OS	S=Cricetulus griseus OX=10	0029 GN=17	79_021800 PE=3 SV=1		0.01	34.3	4	ATP binding, AT	P hyd		-	
< [F.	
	_			_	_				_						_		_	_	
Protein Gr	Protein Cours 2, ACTR 05- Orientulus arteurs 04-40020 CN-44th 05-2 SV-1																		
Fluteni Git	Protein Group 2 - ACIB US=Cricetulus griseus UX=10029 GN=Actb PE=3 SV=1																		
	Prote	ins in Group			Peptides in Group														
N Unus	ed Total		Acce	essia Pep	Peptide Locus Contrib Conf [▽] Sequence Modifications Protein					1 Sc Cleavages AMass				Obs MW	z Spe	ectr 🔺			
2 24.	05 24.04	tr G3GVD0 G3	GVD0_CRIGR		35.001	2.00	99	AGFAGDDAPR				17			-0.0005	975.440	5 2 1.1.1.667	.8	
					47.001	2.00	99	DL TD YLMK			ſ	42			0 0000	997.478	2 1.1.1.136	1.4	
					53.001	2.00	99	DL YANT VLS GG TTMYP G	GI ADR			Pon	tida	identifica	tions	2214.0643	2 3 1.1.1.151	2.1	
					52.001	0.00	99	DI.VANTULSCOTTINPO	T AND	Deamidated(N)@5		i ep	liue	uentinea	10113	2214.0643	3 1.1.1.151	1.1 🔨	
· · ·																		•	
																		_	
Fragmenta	tion Evider	nce																	
																		_	
AG	FAGDDAPR																		
Residue	a	b	b+2	v	¥+2	*	1	[الص		41 II	1		الجبرا العبر		اهي ا	ا امر		
A	44.0495	72.0444	36.5258	976.4483	488.7278		1.5e4 -	12 "	b3	v7x42 b5/8+2 v9+2	10002	b6	75	h7 h8	b9	,0	70		
G	101.0709	129.0659	65.0366	905.4112	453.2092	sity	1.0e4	120.082 a3	a	4 a5		_		111 C.C.			a10		
F	248.1394	276.1343	138.5708	848.3897	424.6985	te			276,135		488.7	Frag	gme	nt identific	cations				
A	319.1765	347.1714	174.0893	701.3213	351.1643	-	5.0e3	191.119 210.113	319.177	347 171 424 701	4581		670 hee						
G	376.1979	404.1928	202.6001	630.2842	315.6457		0.0e0 +		. I , , , ,		<u>ال ال</u>	,	5/3/200	╷╶╷╢╶╷╶╷╢		L			
D	491.2249	519.2198	260.1135	573.2627	287.1350		100	150 200 250	0 300	350 400 45	50 5	00 5	50 6	00 650 700	750 80	0 850	900 950		
D	000 004 0	624 2467	247 6270	459 3359	220 6216	-	n/z, Da												

Figure 2. Example of database search results of HCPs using data from DDA and ProteinPilot software. The search results show information of identified HCPs (from top to bottom panel), identified proteins including the sequence coverage of the proteins, identified peptides associated with the selected protein and the MS/MS fragment assignments for each peptide.

(a) MS1-based quantification method set up

									Import	♥ Export	Options 🔹	
Row IS		IS	Group	Name	Precursor (Q1) Mass (Da)	Precursor (Q1) Fragment (Q3) Mass (Da) Mass (Da)		XIC Retention Width (Da) Time Mode		IS Name	Experiment Index	
•	1		Lysoso	Lysosomal_1	687.83973		0.02	RT value	17.781	BSA_1	1 +TOF MS (350 - 1200)	
	2		Actin	Actin_1	488.72778		0.02	RT value	12.218	BSA_1	1 +TOF MS (350 - 1200)	
	3	\checkmark	IS	BSA_1	461.74765		0.02	RT value	15.218		1 +TOF MS (350 - 1200)	
	4							RT value				

(b) MS/MS-based quantification method set up

	Import 👻											
	Row	IS	Group	Name	Precursor (Q1) Mass (Da)	Fragment (Q3) Mass (Da)	XIC Width (Da)	Retention Time Mode	Retention Time (min)	IS Name	Experiment Index	Find components Table settings
►	1		Lysoso	LYQSMNSQYLK +2y9	687.83973	1098.5248	0.02	RT value	17.781	IS_Sum.IS	25 +TOF MSMS (200 - 1500)	Annord Massas to Component Name
	2		Lysoso	LYQSMNSQYLK +2y8	687.83973	970.4662	0.02	RT value	17.781	IS_Sum.IS	25 +TOF MSMS (200 - 1500)	Append Masses to Component Name
	3		Lysoso	LYQSMNSQYLK +2b3	687.83973	405.213	0.02	RT value	17.781	IS_Sum.IS	25 +TOF MSMS (200 - 1500)	Mass Reconstruction
	4		Actin	AGFAGDDAPR +2y7	488.72778	701.321	0.02	RT value	12.218	IS_Sum.IS	28 +TOF MSMS (200 - 1500)	 Sum Multiple Ions
	5		Actin	AGFAGDDAPR +2y6	488.72778	630.284	0.02	RT value	12.218	IS_Sum.IS	28 +TOF MSMS (200 - 1500)	Ground
	6		Actin	AGFAGDDAPR +2b3	488.72778	276.134	0.02	RT value	12.218	IS_Sum.IS	28 +TOF MSMS (200 - 1500)	Gloups
	7	\checkmark	IS	BSA_1	461.74765	722.408	0.02	RT value	15.218		7 +TOF MSMS (200 - 1500)	Internal Standards
	8	\checkmark	IS	BSA_2	461.74765	575.34	0.02	RT value	15.218		7 +TOF MSMS (200 - 1500)	
	9		IS	BSA 3	461.74765	201.087	0.02	RT value	15.218		7 +TOF MSMS (200 - 1500)	

Figure 3. Processing method set up for HCP quantification in SCIEX OS software. The MS1-based quantification method only requires the *m*/*z* of the precursor ion of the selected signature peptides and the retention time information (a). The MS/MS-based quantification method can be based on 1 fragment or sum of user-specified fragments. Here, the most intense 3 fragments of the signature peptides were used for peak integration and automatically summed for quantification (b).



HCP quantification

After identification of the HCPs of interest, the first step for reliable HCP quantification is to select the appropriate peptide(s) for each identified HCP. There are a few selection criteria: the selected peptides should be unique to the protein, provide good ionization, not suffer from high background interferences and not have any missed cleavages or carry any variable post-translation modifications (PTMs). In case of MS/MS-based quantification an additional criterium to look out for is good fragmentation efficiency. A user can decide on the number of peptides or transitions to be considered ensuring reliable quantification. Here, 1 peptide was used for MS1 and 3 transitions were used for MS/MS-based quantification as an example (Figure 3–5).

After database searching of the data derived from DDA, 2 HCPs from the CHO database were confidently identified in all purification steps, lysosomal protective protein and actin cytoplasmic 1 protein. These 2 proteins were used to showcase both quantification approaches. As a first step, a quantification method was set up in SCIEX OS software leveraging the MS1 information from DDA data (Figure 3a). As mentioned above, this approach did not require any additional optimization, 1 injection was used for identification and quantification, simultaneously.

Across the different purification stages, a clear decrease of the identified HCP lysosomal protective protein from early-stage material to the final BDS was found (Figure 4). As expected, the solvent blank did not show any peak for the lysosomal protective protein. While trends can be observed based on changes of the peak area of the extracted ion chromatograms (XIC), SCIEX OS software allows for flexibility in quantification. Here, ppm values were calculated based on area ratios of the HCP peptide and a selected peptide of the spiked-in BSA at known amount.

For the second HCP, actin cytoplasmic 1, no distinct peak could be used for quantification due to interferences from matrix at MS1 level (Figure 6, right). To this end, the MS/MS-based MRM^{HR} quantification approach was leveraged, which provided the benefit of improving the specificity and sensitivity. The 3 most abundant transitions from the same signature peptide, which were targeted for MS1-based quantification, were used for MS/MS-based quantification (see quantification method setup in Figure 3b). Distinctive peaks from the sum of XICs of the selected fragments could be observed in all HCP samples resulting from the improved specificity by MRM^{HR} (Figure 5).

Blank	Blank_BSA_MRMHR_50ppm2), (sample Index: 1) Area: N/A, Height: N/A, RT: N/A min		Index	Sample Name 🛛 🏹	Component Name ♥	Area ♥	Area Ratio 🛛	Reten ⊽ Time	Precursor Mass ♥	*PPM 🔽			
	17.5 • 18.0 Time min		1	Blank_BSA_MRMHR_50ppm_01	Lysosomal_1	N/A	N/A	N/A	687.8397	N/A			
	Area: 1.142e3, Height: 2.345e2, RT: 17.80 min		5	Blank_BSA_MRMHR_50ppm_02	Lysosomal_1	N/A	N/A	N/A	687.8397	N/A			
BDS	200-		9	Blank_BSA_MRMHR_50ppm_03	Lysosomal_1	N/A	N/A	N/A	687.8397	N/A			
	17.5 18.0		13	HCP_BDS_MRMHR_100ug_01	Lysosomal_1	1.142e3	7.626e-2	17.80	687.8397	3.785			
	HCP_VFpool_MRMHR_100ug2), (sample Index: 1) Area: 8.313e2, Height: 1.681e2, RT: 17.84 min		17	HCP_BDS_MRMHR_100ug_02	Lysosomal_1	1.336e3	9.123e-2	17.93	687.8397	4.557			
VE pool	100		21	HCP_BDS_MRMHR_100ug_03	Lysosomal_1	1.163e3	7.034e-2	17.85	687.8397	3.662			
	17.5 18.0		25	HCP_VFpool_MRMHR_100ug_01	Lysosomal_1	8.771e2	5.347e-2	17.82	687.8397	2.717			
	Time min HCP_CEX_MRMHR_100ug_02), (sample index: 1)		29	HCP_VFpool_MRMHR_100ug_02	Lysosomal_1	8.313e2	4.601e-2	17.84	687.8397	2.359			
OFY	Area: 6.356e3, Height: 1.276e3, RT: 17.80 min		33	HCP_VFpool_MRMHR_100ug_03	Lysosomal_1	8.786e2	5.156e-2	17.86	687.8397	2.671			
CEX	0		37	HCP_CEX_MRMHR_100ug_01	Lysosomal_1	6.356e3	3.659e-1	17.80	687.8397	18.175			
	17.5 18.0		41	HCP_CEX_MRMHR_100ug_02	Lysosomal_1	6.179e3	3.489e-1	17.80	687.8397	17.475			
	Area: 1.307e4, Height: 2.269e3, RT: 17.78 min		45	HCP_CEX_MRMHR_100ug_03	Lysosomal_1	6.528e3	3.649e-1	17.92	687.8397	18.213			
ProA	17.782	►	49	HCP_ProA_MRMHR_100ug_01	Lysosomal_1	1.307e4	2.828e-1	17.78	687.8397	14.092			
	17.5 1 8.0		53	HCP_ProA_MRMHR_100ug_03	Lysosomal_1	1.158e4	2.596e-1	17.84	687.8397	12.561			
Lysosomal_1	r			·			·						
15 Wata 10 5 0	cscmal_1 15 10 HCP_BDS_MRMHR_100ug_01 HCP_BDS_MRMHR_100ug_02 HCP_BDS_MRMHR_100ug_03 HCP_VFpool_MRMHR_100ug_03 HCP_VFpool_MRMHR_100ug_03 HCP_VFpool_MRMHR_100ug_03 HCP_VFpool_MRMHR_100ug_03												
Blk_1	Blk_2 Blk_3 BDS	_1	BDS	S_2 BDS_3 VF pool_1 V	F pool_2 VF po	ol_3 CEΣ	(_1 CEX_2	CEX	3 ProA_	1 ProA_3			

Figure 4. MS1-based quantification for lysosomal protective protein using the DDA data. Left: samples from different purification stages from final drug to early purification stage material, including blank, BDS, VF pool, CEX and ProA. Middle: peak integration of *m*/*z* of the signature peptide. Right: quantification results table with areas, area ratios related to BSA standard, retention times, precursor m/z information and ppm calculation related to BSA standard. Bottom: Plot of ppm values of lysosomal protective protein across the purification stages analyzed in duplicates or triplicates as indicated.



Bla	nk	Blank_BSA_MRN Area: N/A, Heig Area: N/A, Heig Area: N/A, Heig 100 - 0	VIHRsample Index: 1) ht: N/A, RT: N/A min	I	ndex	Sample Name	V	Component Name ▽	Area ⊽	Area Ratio 🛛	Retent _∀ Time	*PPM 💎
		HCP_BDS_MRM	12.0 - 12.5 Time. min HR_1ample Index: 1)		18	Blank_BSA_MRMHR_50ppm_01		Actin_Sum	N/A	N/A	N/A	N/A
		Area: 9.079e2, H	Hei1e2, RT: 12.25 min 12.250		38	Blank_BSA_MRMHR_50ppm_02		Actin_Sum	N/A	N/A	N/A	N/A
BD	DS	100 -	A		58	Blank_BSA_MRMHR_50ppm_03		Actin_Sum	N/A	N/A	N/A	N/A
		- ol	12.0 12.5		78	HCP_BDS_MRMHR_100ug_01		Actin_Sum	9.292e2	1.583e-2	12.21	0.791
		HCP_VFpool_M Area: 3.087e2,	Time min IRMHRample Index: 1) Hei0e1, RT: 12.33 min		98	HCP_BDS_MRMHR_100ug_02		Actin_Sum	9.079e2	1.609e-2	12.25	0.804
VEn	pool	<u>≩</u> 40	12.331		118	HCP_BDS_MRMHR_100ug_03		Actin_Sum	6.424e2	1.175e-2	12.22	0.588
		<u>환</u> 20 · 0 ·			138	HCP_VFpool_MRMHR_100ug_01		Actin_Sum	2.314e2	4.384e-3	12.23	0.219
		HCP_CEX_MRM	11.5 12.0 12.5 13.0 Time min IHR_10ample Index: 1)		158	HCP_VFpool_MRMHR_100ug_02		Actin_Sum	3.187e2	5.753e-3	12.27	0.288
	EX	Area: 8.907e3,	Hei2e3, RT: 12.23 min		178	HCP_VFpool_MRMHR_100ug_03		Actin_Sum	3.087e2	5.726e-3	12.33	0.286
CE		1000 -			198	HCP_CEX_MRMHR_100ug_01		Actin_Sum	1.017e4	1.767e-1	12.25	8.834
		12.0 1 2.5			218	HCP_CEX_MRMHR_100ug_02		Actin_Sum	8.907e3	1.477e-1	12.23	7.383
		Area: 2.728e5,	MHR_1ample Index: 1) Hei1e4, RT: 12.22 min		238	HCP_CEX_MRMHR_100ug_03		Actin_Sum	8.974e3	1.497e-1	12.34	7.484
Pro	A	Ai 4e4 -	12.219	►	258	HCP_ProA_MRMHR_100ug_01		Actin_Sum	2.728e5	2.091e0	12.22	104.532
		0e0 -	12.0 12.5		278	HCP_ProA_MRMHR_100ug_03		Actin_Sum	2.761e5	2.222e0	12.27	111.120
Aastin_Sum			Time. min									
100 -												
-											HCP_ProA_MRN	HK_1000g_01
튭 50-												
	Blank BSA I	HC	CP_BDS_MRMHR_100ug_01	н	ICP_BDS_MR	MHR_100ug_02 HCP_BDS_MRMHR_100ug_03		F	ICP_CEX_MRMHR_100ug_0	1 HCP_CEX_MRM	HR_100ug_03	
0-la Bl	k_1	Blk_2	Blk_3 BD	S_1	BD	S 2 BDS 3 VF pool_1	V	pool_2 VF pool_3	CEX_1	CEX 2 CE	X_3 Pro	A_1 ProA_3

Figure 5. MS/MS-based quantification of actin cytoplasmic 1 with an MRM^{HR} **approach.** Left: samples from different purification stages from final drug to early purification stage material, including blank, BDS, VF pool, CEX and ProA. Middle: peak integration of *m*/*z* of the sum of the most abundant 3 fragments of the signature peptide. Right: quantification results table with areas, area ratios related to BSA standard, retention times and ppm calculation related to BSA standard. Bottom: Plot of ppm values of actin across the purification stages analyzed in duplicates or triplicates as indicated.



Figure 6. XICs from MRM^{HR} and DDA data of actin cytoplasmic protein 1 in BDS. Examples show two fragments used for quantification at MS/MS level (*y*7 and *y*6) as well as the XIC for the related precursor for MS1-based quantification. Significantly better S/N was observed XICs from fragment ion using MRM^{HR} (left and middle) compared to MS1-based XIC (right).



With that approach, the actin cytoplasmic 1 protein was determined to be at 0.73 ppm and 0.26 ppm in BDS and VF pool, respectively. The results show that MRM^{HR} achieved sensitivities down to the sub-ppm level. This can be attributed to the XICs of the selected fragments showing little to no background compared to the XIC of the precursor at MS1 (Figure 6). Summing of intense fragments with low background can further enhance the sensitivity of the assay. Overall, a decreasing trend of actin was observed from the early-stage material to the final drug, indicating the purifications steps successfully removed a large part of the HCP impurities.

Results from a ligand-binding assay determined the total HCP amount to be around 1 ppm in the final BDS sample (data not shown) compared to ~4 ppm of lysosomal protective protein and <1 ppm of actin based on LC-MS analysis. While for some HCPs and samples good correlation between ligand-binding assays and LC-MS can be found, it is crucial to understand that both assays are fundamentally different and not all information can be bridged. Each assay has its advantages and drawbacks for different scenarios and user-needs. Overall ligand-binding assays are easy to use and have increased throughput capabilities. On the other hand, LC-MS analyses can determine the identity of the proteins, which enables efficient risk management and targeted development of purification processes. Furthermore, changes within the HCP content even if the overall amount stays the same - can be detected with LC-MS whereas a ligand-binding assay would be blind to such changes. While detection of HCPs in a ligand-binding assay is dependent on the effectiveness of antibodies raised in a host, ionization efficiency is needed for detection in an LC-MS assay. In sum, having versatile assays in the toolbox for HCP determination is key to ensuring safe and effective drugs.

Conclusions

- Versatility and flexibility for robust and highly confident identification and quantification of HCPs meeting different user needs is offered through DDA, MRM^{HR} and SWATH acquisition featured on the ZenoTOF 7600 system
- Highly confident identification of HCPs from early purification stages all the way to final DS of biotherapeutic samples is achieved by high-resolution MS/MS generated by DDA
- Streamlined identification and quantification of HCPs was demonstrated using MS1-based quantification in SCIEX OS software, leveraging a 1-injection workflow
- Superior quantitative performance for HCPs reaching subppm levels can be achieved on the ZenoTOF 7600 system with MRM^{HR}
- Quantification of all detectable proteins based on MS/MS without extensive LC-MS method development can be achieved with SWATH acquisition

References

1. Huang, Lihua, et al. (2017) A novel sample preparation for shotgun proteomics characterization of HCPs in antibodies. <u>Anal.</u> <u>Chem. 89(10): 5436-5444</u>.

2. Takashi Baba, Pavel Ryumin, Eva Duchoslav et al. (2021) Dissociation of biomolecules by an intense low-energy electron beam in a high sensitivity time-of-flight mass spectrometer. <u>J.</u> *Am. Soc. Mass Spectrom.* **32**(8):1964-1975.

3. Qualitative flexibility combined with quantitative power using the ZenoTOF 7600 system. <u>SCIEX Technical note, RUO-MKT-10-13322-A.</u>

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks).

© 2022 DH Tech. Dev. Pte. Ltd. RUO-MKT-02-14687-A



Headquarters 500 Old Connecticut Path | Framingham, MA 01701 USA Phone 508-383-7700 sciex.com

International Sales For our office locations please call the division headquarters or refer to our website at sciex.com/offices